IRIS
LANZILLO, ROBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 12.075
NA - Nord America 10.604
EU - Europa 8.528
SA - Sud America 1.512
AF - Africa 304
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 7
Totale 33.051
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.135
SG - Singapore 5.188
RU - Federazione Russa 3.456
CN - Cina 2.310
VN - Vietnam 2.111
IT - Italia 1.895
BR - Brasile 1.190
HK - Hong Kong 988
NL - Olanda 750
DE - Germania 635
FR - Francia 470
GB - Regno Unito 311
IN - India 284
CA - Canada 275
FI - Finlandia 268
JP - Giappone 233
BD - Bangladesh 193
UA - Ucraina 156
KR - Corea 138
AR - Argentina 133
IE - Irlanda 132
MX - Messico 103
ZA - Sudafrica 91
CI - Costa d'Avorio 79
SE - Svezia 78
IQ - Iraq 74
ES - Italia 73
PH - Filippine 73
PL - Polonia 66
TH - Thailandia 63
AT - Austria 59
IR - Iran 59
ID - Indonesia 58
EC - Ecuador 45
TR - Turchia 44
CO - Colombia 37
PK - Pakistan 37
TW - Taiwan 36
LT - Lituania 33
BE - Belgio 28
VE - Venezuela 25
MA - Marocco 23
PE - Perù 21
SA - Arabia Saudita 21
EG - Egitto 18
JO - Giordania 18
AE - Emirati Arabi Uniti 17
NP - Nepal 17
PY - Paraguay 17
CL - Cile 16
MY - Malesia 16
TN - Tunisia 15
BO - Bolivia 13
KE - Kenya 13
CZ - Repubblica Ceca 12
NI - Nicaragua 12
AU - Australia 11
DO - Repubblica Dominicana 11
DZ - Algeria 11
HN - Honduras 11
IL - Israele 11
JM - Giamaica 11
UZ - Uzbekistan 11
BG - Bulgaria 10
AM - Armenia 9
CR - Costa Rica 9
DK - Danimarca 9
MK - Macedonia 9
UY - Uruguay 9
CH - Svizzera 8
LB - Libano 8
NG - Nigeria 8
OM - Oman 8
RS - Serbia 8
AZ - Azerbaigian 7
ET - Etiopia 7
PT - Portogallo 7
RO - Romania 7
TT - Trinidad e Tobago 7
GR - Grecia 6
NZ - Nuova Zelanda 6
SK - Slovacchia (Repubblica Slovacca) 6
AL - Albania 5
GT - Guatemala 5
KZ - Kazakistan 5
MN - Mongolia 5
SN - Senegal 5
BB - Barbados 4
CU - Cuba 4
HR - Croazia 4
KH - Cambogia 4
MD - Moldavia 4
MT - Malta 4
PA - Panama 4
QA - Qatar 4
SV - El Salvador 4
XK - ???statistics.table.value.countryCode.XK??? 4
BH - Bahrain 3
GE - Georgia 3
GF - Guiana Francese 3
Totale 32.960
Salva come PNG Salva come JPEG
Città #
Singapore 2.473
San Jose 1.824
Ashburn 971
Hong Kong 948
Moscow 824
Chandler 700
Amsterdam 678
Ho Chi Minh City 614
Beijing 613
Hefei 604
Santa Clara 496
Secaucus 459
Hanoi 454
Naples 434
Los Angeles 303
Lauterbourg 250
Tokyo 220
The Dalles 217
Millbury 213
New York 181
Dallas 168
Napoli 161
Munich 157
Des Moines 136
Princeton 130
Buffalo 127
Boston 117
Nanjing 115
São Paulo 112
Redondo Beach 107
Seoul 107
Milan 104
Da Nang 98
Council Bluffs 93
Helsinki 85
Lawrence 84
Frankfurt am Main 83
Rome 83
Ottawa 80
Haiphong 79
Seattle 78
Wilmington 74
Chicago 69
Montreal 63
Orem 61
Denver 60
Toronto 59
London 57
Warsaw 55
Norwalk 53
Houston 50
Brooklyn 48
Johannesburg 47
Mexico City 46
Turku 46
Chennai 45
Falkenstein 45
Jacksonville 43
Stockholm 43
Phoenix 42
Dublin 41
Nuremberg 39
Rio de Janeiro 38
Tianjin 38
Atlanta 36
Krefeld 33
Poplar 32
Pune 31
Lappeenranta 29
Biên Hòa 28
Dong Ket 28
Nanchang 28
Hải Dương 27
Can Tho 26
Belo Horizonte 25
Brasília 25
Vienna 25
Baghdad 24
San Francisco 24
Augusta 22
Bangkok 22
Paris 22
Washington 22
Shenzhen 21
Charlotte 20
Ankara 19
Bari 19
Jiaxing 19
Newark 19
Curitiba 18
Hebei 18
Thái Nguyên 18
Fairfield 17
Manchester 17
Mumbai 17
Phủ Lý 17
Porto Alegre 17
Woodbridge 17
Amman 16
Bắc Giang 16
Totale 17.756
Salva come PNG Salva come JPEG
Nome #
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 1.019
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 280
Nuove tecniche di imaging nello studio delle alterazioni perfusionali cerebrali e dei processi di degenerazione neuronale in soggetti affetti da sclerosi multipla e da altre patologie neurologiche degenerative. Associazioni tra marcatori radiologici e polimorfismi genetici di predisposizione e decorso delle malattie neurodegenerative 255
Quality of Life and Cognitive function in pediatric and young adults multiple sclerosis: a cross-sectional study 234
Deciphering the role of protein kinase A in the control of FoxP3 expression in regulatory T cells in health and autoimmunity 222
Uric acid: a potential biomarker of multiple sclerosis and of its disability 209
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 186
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 185
Glatiramer Acetate modulates ion channels expression and calcium homeostasis in B cell of patients with relapsing-remitting multiple sclerosis 185
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 183
MRI features suggestive of gadolinium retention do not correlate with Expanded Disability Status Scale worsening in Multiple Sclerosis 182
Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration 177
Affective disorders and Health-Related Quality of Life (HRQoL) in adolescents and young adults with Multiple Sclerosis (MS): the moderating role of resilience 170
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. 169
Vascular alterations in multiple sclerosis and amyotrophic lateral sclerosis : preliminary analysis of susceptibility factors 169
The use of medical-grade cannabis in patients non-responders to Nabiximols 168
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 168
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 166
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 165
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 163
Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study 161
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 161
SPG5 and multiple sclerosis: clinical and genetic overlap? 159
JCV antibodies index on natalizumab treatment: fluctuations and seroconversion. 159
La sclerosi multipla in età pediatrica ed adolescenziale 158
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 158
A new POLG1 mutation with peo and severe axonal and demyelinating sensory-motor neuropathy. 157
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 156
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 155
Quality of life and cognitive functions in early onset multiple sclerosis 153
Epileptic seizures in multiple sclerosis: clinical and EEG correlations. 152
In vivo dentate nucleus MRI relaxometry correlates with previous administration of Gadolinium-based contrast agents 152
Multiple sclerosis and headache co-morbidity. A case-control study 151
Imaging of brain perfusion in multiple sclerosis and neurodegenerative disorders: association with endothelial factors. An interim analysis. In MULTIPLE SCLEROSIS JOURNAL (Vol. 20, pp. 297-297). 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD. 150
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 150
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 149
L'attenzione alle donne nei servizi psicologici offerti dal Centro Regionale Sclerosi Multipla ''Federico II'' di Napoli: l'esperienza del progetto SIM 149
Signs and symptoms of COVID-19 in patients with multiple sclerosis 148
Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosis progression 148
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 147
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 147
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 146
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study (Journal of Neurology, (2022), 269, 6, (3301-3307), 10.1007/s00415-022-11009-x) 146
Modifications of brain tissue volumes in facioscapulohumeral dystrophy. 146
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 145
Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. NeuroImage18: 360-366, 2003.. 145
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 145
Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. 144
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 144
Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential 144
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 143
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 143
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 143
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 143
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 143
Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 142
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 142
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 142
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 142
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 141
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 141
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 141
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 139
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 139
Biochemical parameters alterations in multiple sclerosis: a longitudinal study and review of the literature. 139
Cerebellar lobule atrophy and disability in progressive MS 139
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 138
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 138
Retinal vascular density in multiple sclerosis: a one year follow up 137
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 136
Brain Susceptibility Changes in a Patient with Natalizumab-Related Progressive Multifocal Leukoencephalopathy: A Longitudinal Quantitative Susceptibility Mapping and Relaxometry Study 136
Multiple Sclerosis in the Campania Region (South Italy): Algorithm Validation and 2015-2017 Prevalence 136
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 135
Analysis of macrodeletions in the dystrophin gene in patients from southern Italy and correlation between genotype and phenotype. The presence/absence of the III hinge region of the dystrophin protein affects the phenotype. 135
Lack of correlation between extracranial venous abnormalities and multiple sclerosis: a quantitative MRI study 135
Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak 135
Reduced Annexin A1 Expression Associates with Disease Severity and Inflammation in Multiple Sclerosis Patients 134
Increased endothelin-1 serum levels in patients with multiple sclerosis 134
Vitamin D in a population of Southern Italy relapsing remitting and secondary progressive multiple sclerosis patients. 133
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 133
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 132
Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis 132
Pregnancy Epigenetic Signature in T Helper 17 and T Regulatory Cells in Multiple Sclerosis 132
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 132
A multiple n-glucosylated peptide epitope efficiently detecting antibodies in multiple sclerosis 132
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice 132
Exploring the relation between reserve and fatigue in multiple sclerosis 131
Mobitz type I and II atrioventricular blocks during fingolimod therapy 131
Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience 131
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 130
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 130
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 130
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery 129
Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report 128
Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b. 128
The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis 128
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 128
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions 127
The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. 127
An open label randomised clinical trial of atorvastatin in combination with IFN beta-1a in active MS patients: 12 months results. 127
Totale 15.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.675
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.675
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.154 15 1 9 14 24 85 18 52 123 103 236 474
2022/20232.133 226 187 51 103 222 250 166 156 310 315 106 41
2023/20241.532 62 225 227 94 83 177 72 139 26 40 245 142
2024/20258.348 418 436 52 119 277 521 854 562 618 873 2.822 796
2025/202618.055 1.791 1.839 1.711 1.702 2.925 875 1.999 1.148 2.005 1.173 461 426
2026/2027173 173 0 0 0 0 0 0 0 0 0 0 0
Totale 33.751